Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

NCT ID: NCT03992911

Last Updated: 2019-06-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 336 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-19
• Study Completion Date: 2023-06-20

Brief Summary

This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of Simmtecan and the 5-FU/LV regimen (FOLFSIM regimen) plus Toripalimab. Phase III is aimed to verify inferiority of the overall survival of FOLFSIM regimen plus Toripalimab in comparison with EP/EC in advanced or metastatic neuroendocrine cancer.

Detailed Description

This is a Phase II/III, randomized, two-part, multi-center study, in which subjects with advanced or metastatic neuroendocrine carcinoma will be enrolled.

This study will be conducted in two parts:

Part 1, the Phase II study was to: (i) evaluate the safety and tolerability of the FOLFSIM regimen plus Toripalimab; and (ii) identify the recommended dose; (iii) assess the antitumor activity; (iv) the pharmacokinetic (PK) parameters of the drugs in the regimen.

Part 2, the Phase III study was to verify inferiority of FOLFSIM regimen plus Toripalimab compared with the current standard chemotherapy (EP/EC regimen) in the first-line treatment of advanced or metastatic neuroendocrine carcinoma.

Conditions

Neuroendocrine Carcinoma of the Bladder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FOLFSIM Plus Teripalimab

Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab

Group Type: EXPERIMENTAL

Simmtecan, 5-FU and l-LV

Intervention Type: DRUG

Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.

Toripalimab

Intervention Type: DRUG

Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.

EP/EC

Etoposide plus Cisplatin or Carboplatin

Group Type: ACTIVE_COMPARATOR

Etoposide, Cisplatin

Intervention Type: DRUG

Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.

Etoposide, Carboplatin

Intervention Type: DRUG

Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.

Interventions

Simmtecan, 5-FU and l-LV

Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.

Intervention Type: DRUG

Toripalimab

Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.

Intervention Type: DRUG

Etoposide, Cisplatin

Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.

Intervention Type: DRUG

Etoposide, Carboplatin

Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.

Intervention Type: DRUG

Other Intervention Names

FOLFSIM regimen; JS001; EP regimen; EC regimen

Eligibility Criteria

Inclusion Criteria

1. Signed informed-consent form.

2. Male and Female aged between 18-75 years.

3. Histologically confirmed locally advanced or metastatic nonfunctional poorly-differentiated G3 neuroendocrine carcinoma(NEC), including small cell NEC, large cell NEC and MANEC.

4. Unresectable, including local advanced, recurrent or metastatic disease:

Patients who had progressed after first-line platinum-based regimen or intolerance for treatment, or unwilling to receive current standard chemotherapy (only for phase II); Patients who has received no systemic chemotherapy, or relapsed at least 6 months since completion of adjuvant chemotherapy or radiotherapy.

5. At least 1 measurable lesion according to RECIST criteria;

6. Providing with tumor specimen (for testing the expression of PD L1 and the infiltrating lymphocytes);

7. Eastern Cooperative Oncology Group (ECOG) 0-1;

8. Adequate liver, kidney and bone marrow function; Screening laboratory values must meet the following criteria: hemoglobin ≥ 10.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1.5 x ULN, creatinine clearance >60ml/min (CockcroftGault equation), INR≤1.5, APTT≤1.5 x ULN;

Exclusion Criteria

1. Histologically confirmed well differentiated G3 neuroendocrine tumor;

2. Evidence with active CNS disease or epilepsy;

3. Metastasis over 5 lesions;

4. Prior treatment with CPT-11 or antiPD1/PDL1/CTLA-4 antibody for neoadjuvant or adjuvant therapy;

5. Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix;

6. Predicted survival <3 months;

7. Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, heart block >II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);

8. Any uncontrollable active infection, within past 1 week

9. Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism;

10. History with tuberculosis;

11. The side effects caused by the previous treatment of the subjects did not return to CTCAE ≤1; except hair loss and other tolerable events determined by investigator;

12. Hypersensitivity to Simmtecan or recombinant humanized antiPD1 monoclonal Ab or its components;

13. Prior antitumor therapy (including chemotherapy, target therapy, corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;

14. Patients who received a potent inhibitor or inducer of CYP3A4 within 1 week prior to the first dose;

15. Prior radical radiothearpy within past 4 weeks;

16. Prior major surgery within past 4 weeks (diagnostic surgery excluded);

17. Prior live vaccine therapy within past 4 weeks;

18. Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml);

19. Pregnant or nursing;

20. Males or female of childbearing potential refuse to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.

21. Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University

OTHER

Sponsor Role: lead

Responsible Party

Shen Lin

MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lin Shen

Role: PRINCIPAL_INVESTIGATOR

Peking University

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lin Shen

Role: CONTACT

linshenpku@163.com

86-10-88196561

Facility Contacts

Shen Lin, Professor

Role: primary

Linshenpku@163.com

010-88196561

Other Identifiers

LP-201

Identifier Type: -

Identifier Source: org_study_id